ad

Ninety Five Hundred Crore Revenue Stocks to Buy in November 2026: 5 Names on the Watchlist

Fortis Healthcare Rs 764.00. Ipca Labs Rs 1,884. RR Kabel Rs 1,984. Schaeffler India Rs 3,586. Sundaram Finance Rs 4,339. NSE closing prices, 13 Nov 2026.


16 Nov 2026 • 2:40 pm

Ninety Five Hundred Crore Revenue Stocks to Buy in November 2026: 5 Names on the Watchlist

Quick Answer

Five ninety five hundred crore revenue stocks to buy on the November 2026 watchlist are Fortis Healthcare, Ipca Laboratories, RR Kabel, Schaeffler India and Sundaram Finance. All five grew revenue in their latest full year, and all five also grew net profit. Sundaram Finance has the lowest P/E at 19.62, while Schaeffler India leads on return on equity at 20.39%. Check each valuation against your own risk appetite before acting.

The ninety five hundred crore revenue stocks to buy in November 2026 start with five listed names: Fortis Healthcare, Ipca Laboratories, RR Kabel, Schaeffler India and Sundaram Finance. These five companies each reported FY26 revenue between about Rs 9,178 crore and Rs 9,873 crore, and they range from hospitals to finance.

This article ranks none of them as a sure thing. It lays out the numbers each company has reported, how the shares are priced today and what an investor should check before adding any of these ninety five hundred crore revenue stocks to buy to a portfolio. All prices are NSE closing prices of 13 November 2026, and financials come from company filings.

Click Here – Get Free Investment Predictions

Table of Contents

Which Are the Best Ninety Five Hundred Crore Revenue Stocks to Buy in November 2026?

The best ninety five hundred crore revenue stocks to buy in November 2026 for a watchlist are Fortis Healthcare, Ipca Laboratories, RR Kabel, Schaeffler India and Sundaram Finance. They were picked because each has complete reported financials, profit in the latest quarter and an NSE listing. The table puts their market data side by side.

Company CMP (Rs) Market Cap P/E ROE Dividend Yield
Fortis Healthcare 764.00 Rs 56,890 crore 53.14 10.53% 0.13%
Ipca Laboratories 1,884 Rs 48,860 crore 35.53 14.15% 0.31%
RR Kabel 1,984 Rs 24,951 crore 41.06 19.12% 0.43%
Schaeffler India 3,586 Rs 56,806 crore 43.26 20.39% 0.96%
Sundaram Finance 4,339 Rs 43,563 crore 19.62 13.82% 1.02%

On valuation, Fortis Healthcare trades below the industry P/E; Ipca Laboratories, RR Kabel and Schaeffler India sit close to it; Sundaram Finance carries a premium. Valuation is the first filter for any ninety five hundred crore revenue stocks to buy list, and it is covered again in the risk section.

Why These Ninety Five Hundred Crore Revenue Stocks to Buy Are in Focus

In this list, FY26 net profit and revenue both grew for every company, and quarterly profit in the latest reported quarter was higher than a year earlier for all five. The list covers a hospital chain, a maker of pharma formulations and active ingredients, a wires and cables maker, a maker of bearings and auto components and a vehicle finance company. Investors comparing the best ninety five hundred crore revenue stocks in India usually check earnings growth, margins and how the shares are valued.

Fortis Healthcare: The Multi-City Hospital Network Among Ninety Five Hundred Crore Revenue Stocks to Buy

Fortis Healthcare is a hospital and diagnostics network with large facilities across the country. Its market capitalisation is Rs 56,890 crore, the share price is Rs 764.00 and the P/E of 53.14 compares with an industry P/E of 61.50.

Over FY26, net profit rose 31.5% to Rs 1,064 crore on revenue of Rs 9,178 crore, which was up 16.9%. The latest quarter, the June 2026 quarter, brought revenue of Rs 2,560 crore, up 17.3% year on year, and net profit of Rs 273 crore, up 2.3%.

Return on equity is 10.53%, debt-to-equity is 0.35, and the dividend yield is 0.13%. Promoters hold 31.17%, foreign institutions 23.19% and domestic institutions 34.46% as of September 2026. Domestic institutional holding has risen from 29.14% to 34.46% over the last year.

Ipca Laboratories: The Formulations and API Name Among Ninety Five Hundred Crore Revenue Stocks to Buy

Ipca Laboratories is a pharma company making formulations and active ingredients, known for anti-malarial and pain-management products. The stock trades at Rs 1,884 with a market capitalisation of Rs 48,860 crore and a P/E of 35.53, against an industry P/E of 37.65.

FY26 revenue rose 8.7% to Rs 9,821 crore and net profit rose 51.3% to Rs 1,191 crore. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit grew 80.4% to Rs 423 crore.

Return on equity is 14.15%, debt-to-equity is 0.10, and the dividend yield is 0.31%. Promoters hold 44.72%, foreign institutions 11.53% and domestic institutions 36.59% as of September 2026. Foreign institutional holding has risen from 10.43% to 11.53% over the last year.

Check Ninety Five Hundred Crore Revenue Stocks Live on the Univest Screener

RR Kabel: A Cables Name With Consumer Reach Among Ninety Five Hundred Crore Revenue Stocks to Buy

RR Kabel is a wires and cables maker that also sells fans, lighting and other consumer electricals. At Rs 1,984, the stock has a market capitalisation of Rs 24,951 crore and trades at 41.06 times earnings, while the industry P/E is 39.42.

Reported numbers show FY26 revenue of Rs 9,779 crore, up 27.5% year on year, with net profit at Rs 492 crore, up 58.0%. The September 2026 quarter added revenue of Rs 3,303 crore (up 51.5%) and net profit of Rs 181 crore (up 55.3%).

Return on equity is 19.12%, debt-to-equity is 0.13, and the dividend yield is 0.43%. Promoters hold 59.32%, foreign institutions 12.51% and domestic institutions 10.25% as of September 2026. Foreign institutional holding has risen from 8.18% to 12.51% over the last year.

Schaeffler India: The Global-Backed Bearing Name Among Ninety Five Hundred Crore Revenue Stocks to Buy

Schaeffler India is a supplier of bearings, clutch and engine parts to automotive and industrial customers, part of the German Schaeffler group. Its market capitalisation is Rs 56,806 crore, the share price is Rs 3,586 and the P/E of 43.26 compares with an industry P/E of 42.17.

Over CY2025, net profit rose 22.5% to Rs 1,150 crore on revenue of Rs 9,834 crore, which was up 17.8%. The latest quarter, the September 2026 quarter, brought revenue of Rs 3,122 crore, up 26.8% year on year, and net profit of Rs 349 crore, up 20.7%.

Return on equity is 20.39%, debt-to-equity is 0.01, and the dividend yield is 0.96%. Promoters hold 74.13%, foreign institutions 4.29% and domestic institutions 16.13% as of September 2026.

Sundaram Finance: The Vehicle Finance Veteran Among Ninety Five Hundred Crore Revenue Stocks to Buy

Sundaram Finance is a long-established vehicle finance company in the TVS group. The stock trades at Rs 4,339 with a market capitalisation of Rs 43,563 crore and a P/E of 19.62, against an industry P/E of 16.13.

FY26 revenue rose 15.3% to Rs 9,873 crore and net profit rose 10.6% to Rs 2,005 crore. In the June 2026 quarter, revenue grew 12.8% year on year to Rs 2,653 crore, while net profit grew 38.1% to Rs 569 crore.

Return on equity is 13.82%, and the dividend yield is 1.02%. Promoters hold 37.19%, foreign institutions 17.99% and domestic institutions 8.88% as of September 2026. Domestic institutional holding has risen from 6.84% to 8.88% over the last year.

Download the Univest iOS App or Univest Android App to track these ninety five hundred crore revenue stocks live and get daily stock recommendations.

Growth Snapshot: Latest Full Year and Latest Quarter

The table compares year-on-year growth in revenue and net profit for all five ninety five hundred crore revenue stocks, using filed results.

Company Full-Year Revenue Growth Full-Year Profit Growth Latest Quarter Quarter Revenue Growth Quarter Profit Growth
Fortis Healthcare 16.9% 31.5% Jun 2026 17.3% 2.3%
Ipca Laboratories 8.7% 51.3% Jun 2026 20.2% 80.4%
RR Kabel 27.5% 58.0% Sep 2026 51.5% 55.3%
Schaeffler India 17.8% 22.5% Sep 2026 26.8% 20.7%
Sundaram Finance 15.3% 10.6% Jun 2026 12.8% 38.1%

Factors That Move Ninety Five Hundred Crore Revenue Stocks to Buy

Four factors tend to drive ninety five hundred crore revenue stocks, and each one is worth checking before a purchase.

  • Revenue scale: Each reported above Rs 9,100 crore.
  • Dividends: Sundaram Finance yields about 1.0%.
  • Return on equity: Schaeffler India leads at about 20%.
  • Valuation: P/E runs from about 20 to 53.

Risks to Keep in Mind Before Buying Ninety Five Hundred Crore Revenue Stocks

The first risk is that Fortis Healthcare trades at a P/E near 53, Schaeffler India near 43 and RR Kabel near 41, while Sundaram Finance trades near 20, so expectations differ widely. The second is that Sundaram Finance carries the highest borrowings of the five as a lender and auto parts demand follows vehicle sales. Check results every quarter.

On the numbers, Fortis Healthcare trades at the highest P/E on this list at 53.14, so its earnings need to keep growing to support the price. Ninety Five Hundred Crore Revenue stocks to buy can still fall when markets turn weak, and a staggered entry has historically suited investors better than a lump-sum purchase.

How to Choose Ninety Five Hundred Crore Revenue Stocks to Buy

  • Compare growth: RR Kabel grew FY26 profit most, by about 58%.
  • Check P/E: Sundaram Finance trades lowest.
  • Read the yield: Sundaram Finance pays the most.
  • Spread sectors: Mix hospitals, pharma, cables, auto parts and vehicle finance.

How to Invest in Ninety Five Hundred Crore Revenue Stocks

  1. Shortlist two or three companies from this list that match your risk appetite.
  2. Open the Univest Screener and compare P/E, ROE and debt for each stock.
  3. Check the latest quarterly results and shareholding pattern on NSE or BSE.
  4. Decide an amount you can hold for three to five years and split it into two or three purchases.
  5. Review the holding after every quarterly result instead of reacting to daily price moves.

Conclusion

Sundaram Finance offers the lowest P/E on this list at 19.62, Schaeffler India has the highest return on equity at 20.39%, and RR Kabel posted the fastest net profit growth in its latest full year at 58.0%. Among the best ninety five hundred crore revenue stocks in India, these five give investors a spread of size, valuation and growth, so the right pick depends on risk appetite and holding period. Spread the entry, keep position sizes sensible and consult a SEBI-registered advisor before investing in any of these ninety five hundred crore revenue stocks to buy.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions on Ninety Five Hundred Crore Revenue Stocks to Buy

Which are the best ninety five hundred crore revenue stocks to buy in November 2026?

Ans. The five ninety five hundred crore revenue stocks on the November 2026 watchlist are Fortis Healthcare, Ipca Laboratories, RR Kabel, Schaeffler India and Sundaram Finance. Sundaram Finance has the lowest P/E at 19.62, Schaeffler India has the highest ROE at 20.39%, and RR Kabel grew net profit 58.0% in its latest full year. This is educational content, not investment advice, so please consult a SEBI-registered advisor.

Is Fortis Healthcare a good stock to buy from this Ninety Five Hundred Crore Revenue list?

Ans. Fortis Healthcare is the largest company on this list with a market capitalisation of Rs 56,890 crore and a P/E of 53.14 against an industry P/E of 61.50. Its FY26 revenue rose 16.9% and net profit rose 31.5%, with return on equity at 10.53%. Whether it suits you depends on your risk appetite and holding period, so please consult a SEBI-registered advisor before investing.

Are these ninety five hundred crore revenue stocks expensive right now?

Ans. Valuations vary across the group. Fortis Healthcare trades at a P/E of 53.14, Ipca Laboratories trades at a P/E of 35.53, RR Kabel trades at a P/E of 41.06, Schaeffler India trades at a P/E of 43.26, Sundaram Finance trades at a P/E of 19.62, against industry multiples ranging from 16.13 to 61.50. Higher multiples reflect faster growth but also leave less room for earnings misses, so entry price deserves attention.

Which of these ninety five hundred crore revenue stocks pay a dividend?

Ans. Dividend yields on this list are Fortis Healthcare 0.13%, Ipca Laboratories 0.31%, RR Kabel 0.43%, Schaeffler India 0.96%, Sundaram Finance 1.02%. Yields are modest across the group, so most investors look at these stocks for growth in earnings rather than for income, and payouts can change with company profits.

Which stock on this list has the highest return on equity?

Ans. Schaeffler India has the highest ROE on this list at 20.39%, followed by RR Kabel at 19.12% and Ipca Laboratories at 14.15%. A higher ROE shows a company earns more profit on shareholder capital, but it should be read alongside valuation and debt.

What are the risks of investing in ninety five hundred crore revenue stocks?

Ans. The main risks are high valuations at three names, borrowings at the vehicle lender and a wide spread in sectors. On this list, Fortis Healthcare trades at the highest P/E of 53.14, which leaves less room for earnings disappointments. Staggered buying and a long holding period can help manage these risks.

How can I invest in ninety five hundred crore revenue stocks in India?

Ans. You can buy these stocks directly on NSE or BSE through a demat account, and compare them first on the Univest Screener using P/E, ROE and debt. Many investors split the amount across two or three purchases and review the holding after each quarterly result. Sector-themed mutual funds and ETFs are another route for investors who prefer diversification.

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5
ad

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited

Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003

Write to us : support@univest.in, compliance@univest.in

Verify on SEBI registry →

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store
Stocks:
All|a|b|c|d|e|f|g|h|i|j|k|l|m|n|o|p|q|r|s|t|u|v|w|x|y|z

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down